Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
- Supplementary File 1:
Supplementary (PDF, 350 KiB)
Gouravan, S.; Meza-Zepeda, L.A.; Myklebost, O.; Stratford, E.W.; Munthe, E. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. Int. J. Mol. Sci. 2018, 19, 969. https://doi.org/10.3390/ijms19040969
Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. International Journal of Molecular Sciences. 2018; 19(4):969. https://doi.org/10.3390/ijms19040969
Chicago/Turabian StyleGouravan, Sarina; Meza-Zepeda, Leonardo A.; Myklebost, Ola; Stratford, Eva W.; Munthe, Else. 2018. "Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas" Int. J. Mol. Sci. 19, no. 4: 969. https://doi.org/10.3390/ijms19040969